The Autonomic Progress Bar Motivates Treatment Completion for Patients of Stimulant Use Disorder and Cannabis Use Disorder

被引:3
|
作者
Chen, I-Chun [1 ,2 ]
Teng, Gloria [3 ]
Chen, Chur-Jen [4 ]
Lan, Tsuo-Hung [1 ,5 ]
Liu, Hung-Jen [2 ,6 ]
机构
[1] Taichung Vet Gen Hosp, Dept Psychiat, Taichung, Taiwan
[2] Natl Chung Hsing Univ, PhD Program Translat Med, Taichung, Taiwan
[3] Xiamen Univ Malaysia, Dept Math, Sepang, Selangor, Malaysia
[4] Tunghai Univ, Dept Appl Math, Taichung, Taiwan
[5] Natl Yang Ming Univ, Fac Med, Taipei, Taiwan
[6] Natl Chung Hsing Univ, Inst Mol Biol, Taichung, Taiwan
来源
FRONTIERS IN PSYCHIATRY | 2020年 / 10卷
关键词
mandatory treatment; progress bar; motivation; stimulant use disorder; time series analysis; RANDOMIZED CONTROLLED-TRIAL; SENSITIVITY;
D O I
10.3389/fpsyt.2019.00944
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: The intrinsic motivation behind the "need to complete" is more influential than external incentives. We introduced a novel progress-bar tool to motivate the completion of programs designed to treat stimulant and cannabis use disorders. We further examined the effectiveness of the progress bar's scoring approach in forecasting consistently negative urine tests. Methods: This study's participants included 568 patients with stimulant, amphetamine-type, and cannabis use disorders who were undergoing 12-month mandatory treatment programs at Taichung Veterans General Hospital in Taiwan. Patients were given scores of 1, -1, or 0 depending on whether they received negative, positive, or missing urinalysis reports, respectively. The autonomic progress bar generated weekly score totals. At the group level, score(i) donated scores from all patients for a given week (i denoted the week). Score(i) was standardized to adjusted score(i). We then conducted Autoregressive Integrated Moving Average (ARIMA) Model of time-series analyses for the adjusted score(i). Results: A total of 312 patients maintained treatment progress over the 12-month program. The autonomic score calculator totaled the shared achievements of these patients. The coefficients of the lag variables for mean (p), lag variables for residual error term (q), and number of orders for ensuring stationary (d) were estimated at p = 3, d = 4, and q = 7 for the first half of the treatment program, and were estimated at p = 2, d = 2, and q = 3 for the second half. Both models were stationary and tested as fit for prediction (p < 0.05). Sharply raised adjusted scores were predicted during the high-demand treatment phase. Discussion: This study's novel progress-bar tool effectively motivated treatment completion. It was also effective in forecasting continually negative urine tests. The tool's free open-source code makes it easy to implement among many substance-treatment services.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Randomized controlled trial of zolpidem as a pharmacotherapy for cannabis use disorder
    Lee, Dustin C.
    Schlienz, Nicolas J.
    Herrmann, Evan S.
    Martin, Erin L.
    Leoutsakos, Jeannie
    Budney, Alan J.
    Smith, Michael T.
    Tompkins, Andrew
    Hampson, Aidan J.
    Vandrey, Ryan
    JOURNAL OF SUBSTANCE USE & ADDICTION TREATMENT, 2024, 156
  • [32] Topiramate in the treatment of cocaine use disorder
    Prince, Valerie
    Bowling, Kellie C.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2018, 75 (01) : E13 - E22
  • [33] Validation of the Reasons for Quitting Smoking Cannabis Scale Among People with Cannabis Use Disorder
    Stone, Bryant M.
    Gilbert, David G.
    SUBSTANCE USE & MISUSE, 2024, 59 (13) : 1950 - 1961
  • [34] Gender differences in cannabis use disorder treatment: Change readiness and taking steps predict worse cannabis outcomes for women
    Sherman, Brian J.
    Baker, Nathaniel L.
    McRae-Clark, Aimee L.
    ADDICTIVE BEHAVIORS, 2016, 60 : 197 - 202
  • [35] Preclinical Profile of CM699 as a Medication Candidate for Stimulant Use Disorder
    Hiranita, Takato
    Hong, Weimin C.
    Sharma, Abhisheak
    Lopez, Jessica P.
    Mesangeau, Christophe
    Whittaker, Daniel A.
    Alsharif, Walid
    Kopajtic, Theresa A.
    Jamalapuram, Seshulatha
    Avery, Bonnie A.
    Tanda, Gianluigi
    Mccurdy, Christopher R.
    Katz, Jonathan L.
    ACS CHEMICAL NEUROSCIENCE, 2025, 16 (08): : 1454 - 1468
  • [36] Psychosocial Interventions for Amphetamine Type Stimulant Use Disorder: An Overview of Systematic Reviews
    Tran, Mai Thi Ngoc
    Luong, Quang Hung
    Le Minh, Giang
    Dunne, Michael P.
    Baker, Philip
    FRONTIERS IN PSYCHIATRY, 2021, 12
  • [37] Stimulant use disorder diagnosis and opioid agonist treatment dispensation following release from prison: a cohort study
    Heather Palis
    Bin Zhao
    Pam Young
    Mo Korchinski
    Leigh Greiner
    Tonia Nicholls
    Amanda Slaunwhite
    Substance Abuse Treatment, Prevention, and Policy, 17
  • [38] Accentuate the positive: Cultivating positive affect during treatment for stimulant use disorder can regulate the immune system
    Meade, Christina S.
    Towe, Sheri L.
    BRAIN BEHAVIOR AND IMMUNITY, 2024, 122 : 566 - 567
  • [39] Stimulant use disorder diagnosis and opioid agonist treatment dispensation following release from prison: a cohort study
    Palis, Heather
    Zhao, Bin
    Young, Pam
    Korchinski, Mo
    Greiner, Leigh
    Nicholls, Tonia
    Slaunwhite, Amanda
    SUBSTANCE ABUSE TREATMENT PREVENTION AND POLICY, 2022, 17 (01)
  • [40] Exploring the use of Routine Outcome Monitoring in the treatment of patients with a psychotic disorder
    Tasma, M.
    Liemburg, E. J.
    Knegtering, H.
    Delespaul, P. A. E. G.
    Boonstra, A.
    Castelein, S.
    EUROPEAN PSYCHIATRY, 2017, 42 : 89 - 94